Sara N. Bleich, PhD
Articles
November 20th 2012
Validating the Adapted Diabetes Complications Severity Index in Claims Data
Hsien-Yen Chang, PhD Jonathan P. Weiner, DrPH Thomas M. Richards, MSEE Sara N. Bleich, PhD Jodi B. Segal, MD, MPH
The aDCSI without the inclusion of laboratory data performs similarly to the DCSI with laboratory results, and is a good measure of diabetes severity.
April 23rd 2012
Predicting Costs With Diabetes Complications Severity Index in Claims Data
Hsien-Yen Chang, PhD Jonathan P. Weiner, DrPH Thomas M. Richards, MS Sara N. Bleich, PhD Jodi B. Segal, MD, MPH
The Diabetes Complications Severity Index without laboratory test results is a good measure of diabetes severity, given its ability to explain costs.
Latest Updated Articles
Published: May 9th 2024 | Updated: May 21st 2024
FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors
Published: August 28th 2024 | Updated: September 9th 2024
Illuminating the Future: Dr Kristen Whitney on What's Next for Dermoscopy
Published: August 4th 2024 | Updated: September 9th 2024
Who Should Have Lp(a) Levels Tested? Experts Take Sides
Published: September 3rd 2024 | Updated: September 9th 2024
ASCERTAIN Data: Oral Decitabine-Cedazuridine Outcomes in MDS
Published: September 3rd 2024 | Updated: September 9th 2024
Luspatercept in Lower Risk MDS: Insights on the COMMANDS Trial
Published: August 28th 2024 | Updated: September 9th 2024
TYK2 Inhibitor Zasocitinib Shows High Efficacy, Safety in Moderate to Severe Psoriasis
